Crystalys Raises $130M Series B to Advance Dotinurad in Phase 3
Crystalys Therapeutics closed an oversubscribed $130M Series B on July 22, 2026. Frazier Life Sciences led the financing, which will support late-stage development and commercialization preparation for dotinurad, Crystalys's once-daily oral URAT1 inhibitor for gout.
The round arrives less than 10 months after Crystalys announced a $205M Series A. Across those two disclosed financings, the company has raised $335M to advance a drug already approved in several Asian markets through the studies required to pursue a potential second-line role in the United States and Europe.
That is the strategic point beneath the funding headline. Crystalys is not financing an early scientific experiment. It is financing a global clinical evidence package around an asset with substantial prior patient exposure while recognizing that approvals in Asia do not answer the clinical or regulatory questions that still matter in North America and Europe.
What Happened
The $130M Series B was led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund. Every existing investor named in the announcement also participated, including Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund.
The investor syndicate provides useful context. New crossover and specialist healthcare investors broaden the group watching the next clinical milestones, while full participation from existing backers suggests the investors closest to the program remain willing to finance its remaining development risk. That does not predict clinical success, but it gives Crystalys greater flexibility to execute before financing pressures begin influencing scientific priorities.
Why Dotinurad Is the Center of the Story
Dotinurad is designed to inhibit URAT1, a kidney transporter responsible for reabsorbing uric acid. By reducing that reabsorption, the drug is intended to increase urate excretion and lower serum uric acid, the central biological target in long-term gout management. The American College of Rheumatology continues to recommend allopurinol as first-line urate-lowering therapy within a treat-to-target strategy.
Crystalys is positioning dotinurad for patients whose disease remains inadequately controlled after first-line therapy but before treatment escalates to options typically reserved for refractory disease. That positioning is commercially attractive because gout is both common and chronic. A national prevalence study estimated that approximately 9.2 million U.S. adults had gout during 2015-2016. It is also clinically demanding because any second-line therapy must demonstrate more than a plausible mechanism. It must produce a benefit-risk profile strong enough for physicians, regulators, and payers to change an established treatment pathway.
The Clinical Program the Round Must Fund
Crystalys's JEWEL clinical program includes two registration-directed Phase 3 studies and a Phase 2 study designed for different patient populations.
RUBY (NCT07089875) is designed to compare dotinurad with physician-selected stable-dose allopurinol in approximately 500 adults with hyperuricemia associated with gout across the United States and Europe. TOPAZ (NCT07089888) is enrolling approximately 250 adults with tophaceous gout, a more advanced form of the disease characterized by urate crystal deposits.
AMETHYST (NCT07535034) is a U.S. Phase 2 study enrolling approximately 90 adults who either cannot tolerate xanthine oxidase inhibitors or have not responded to uricase therapy. Together, these studies evaluate the same underlying hypothesis: whether dotinurad can provide clinically meaningful urate control across patient populations whose needs remain insufficiently addressed by the current treatment sequence.
Existing Evidence Lowers Risk, but Does Not Remove It
Dotinurad launched in Japan in 2020 and is now approved in Japan, China, the Philippines, Taiwan, and Thailand. Crystalys says more than 2.2 million patients have received the therapy. A randomized Phase 3 study conducted in China reported that 73.6% of patients receiving dotinurad 4 mg/day achieved the study's serum urate target at Week 24, compared with 38.1% of patients receiving febuxostat 40 mg/day.
Those results make dotinurad a substantially more mature asset than many private biotechnology programs, but they should not be interpreted as a U.S. or European regulatory endorsement. Differences in trial design, patient populations, comparator strategies, and regulatory expectations remain significant. The purpose of the Series B is to resolve those questions through additional evidence rather than assume they have already been answered.
The Team Is Built Around Gout and Late-Stage Execution
Co-founder, President, and CEO James Mackay brings more than 40 years of drug development and commercialization experience, according to the company. The leadership team also includes co-founder and Chief Medical Officer Nihar Bhakta, whose background includes gout clinical development and regulatory work at Ardea Biosciences; co-founder and Chief Operating Officer Ashwin Ram; co-founder and Executive Director of Operations and Business Development DeAnne Reid; and Chief Financial Officer Justin Thacker.
That concentration of gout expertise and commercialization experience is more than executive biography. Phase 3 development consumes capital quickly, and successful late-stage biotechnology execution depends on a long chain of operational discipline, including patient enrollment, site performance, protocol adherence, manufacturing readiness, regulatory engagement, and commercial preparation. Investors can finance those activities, but management must execute them.
What the Series B Signals
Crystalys launched publicly with a $205M Series A in September 2025. Raising another $130M less than a year later reflects continued investor appetite for private biotechnology companies combining late-stage assets, meaningful human clinical experience, and clearly defined commercial opportunities. It also raises expectations because $335M across two disclosed financings buys both runway and accountability.
The next chapter is therefore not another financing announcement. It is whether RUBY, TOPAZ, and AMETHYST can translate international clinical experience into evidence that satisfies regulators and physicians across Western healthcare systems. If Crystalys succeeds, it could establish a credible therapeutic option between first-line allopurinol and treatments reserved for the most difficult cases. If it does not, even one of the strongest investor syndicates in biotechnology will not change the underlying biology.
Biotech funding, last 30 days
DevCuration's funding database tracked 11 Biotech rounds totaling $511.8M in disclosed capital over the past 30 days. Recent deals we covered:
- N-Zyme Biomedical Raises $4.6M for Phase 2 Reflux TrialsSeries A · $4.6M · Jul 23
- Estrigenix Therapeutics Raises $2M Seed Round to Advance ERbeta Women's Health PlatformSeries Seed · $2M · Jul 22
- Mandrake Bio Raises $1.9M Pre-Seed for AI-Native Protein DesignPre-Seed · $1.9M · Jul 21
- Trellis Bioscience Raises $9M Series C for Calpurbatug Phase 2Series C · $9M · Jul 21
- Beeline Medicines Raises $126.3M Series A Extension to Advance Lupus PipelineSeries A Extension · $126.3M · Jul 7
Frequently Asked Questions
Why is Crystalys Therapeutics' Series B strategically important?
The $130M financing supports the Phase 3 RUBY and TOPAZ trials, the Phase 2 AMETHYST study, commercialization preparation, and runway through anticipated clinical and regulatory milestones. It gives Crystalys more operating room to test whether dotinurad can become a second-line gout option in the U.S. and Europe.
What is dotinurad, and where is it approved?
Dotinurad is a once-daily oral selective URAT1 inhibitor designed to lower serum uric acid by increasing urate excretion. It is approved in Japan, China, the Philippines, Taiwan, and Thailand, but remains investigational in North America and Europe.
How do the RUBY, TOPAZ, and AMETHYST studies differ?
RUBY is a Phase 3 study in about 500 adults with hyperuricemia associated with gout, while TOPAZ is a Phase 3 study in about 250 adults with tophaceous gout. AMETHYST is a Phase 2 study in about 90 adults who cannot tolerate xanthine oxidase inhibitors or have failed uricase treatment.
What treatment gap is Crystalys trying to address?
Crystalys is positioning dotinurad as a potential second-line oral therapy for patients who are not adequately controlled on first-line treatment. The intended role sits before therapies generally reserved for refractory gout, but the ongoing clinical program still has to establish the evidence for that position.
What does the Series B investor syndicate signal?
The round combines new specialist and crossover investors with participation from every existing investor named in the announcement. That breadth suggests continued willingness to fund Crystalys through its next clinical milestones, though it does not guarantee trial or regulatory success.
